12 Apr, 2023 36-Month Results from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran) Presented at NKF Spring Clinical Meetings
During the National Kidney Foundation (NKF) 2023 Spring Clinical Meetings, we presented new 36-month results from the ILLUMINATE-A Phase 3 study of lumasiran in patients with primary hyperoxaluria type 1 (PH1).